Bristol-Myers Squibb Co
BMY
View Detailed Chart
52.150USD
+0.195+0.38%
Close 12/05, 16:00（ET）Quotes delayed by 15 min
106.18BMarket Cap
17.58P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.38%
5 Days
+6.00%
1 Month
+11.69%
6 Months
+7.73%
Year to Date
-7.80%
1 Year
-12.18%
View Detailed Chart
TradingKey Stock Score of Bristol-Myers Squibb Co
Currency: USD Updated: 2025-12-05Key Insights
Bristol-Myers Squibb Co's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 13/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 52.62.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bristol-Myers Squibb Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
30
analysts
Hold
Current Rating
52.621
Target Price
+0.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bristol-Myers Squibb Co Highlights
StrengthsRisks
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is 17.55, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.68B shares, decreasing 0.60% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 605.00 shares of this stock.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bristol-Myers Squibb Co Info
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Ticker SymbolBMY
CompanyBristol-Myers Squibb Co
CEOBoerner (Christopher S)
Websitehttps://www.bms.com
FAQs
What is the current price of Bristol-Myers Squibb Co (BMY)?
The current price of Bristol-Myers Squibb Co (BMY) is 52.150.
What is the symbol of Bristol-Myers Squibb Co?
The ticker symbol of Bristol-Myers Squibb Co is BMY.
What is the 52-week high of Bristol-Myers Squibb Co?
The 52-week high of Bristol-Myers Squibb Co is 63.330.
What is the 52-week low of Bristol-Myers Squibb Co?
The 52-week low of Bristol-Myers Squibb Co is 42.520.
What is the market capitalization of Bristol-Myers Squibb Co?
The market capitalization of Bristol-Myers Squibb Co is 106.18B.
What is the net income of Bristol-Myers Squibb Co?
The net income of Bristol-Myers Squibb Co is -8.95B.
Is Bristol-Myers Squibb Co (BMY) currently rated as Buy, Hold, or Sell?
According to analysts, Bristol-Myers Squibb Co (BMY) has an overall rating of Hold, with a price target of 52.621.
What is the Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY)?
The Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY) is 2.971.
Related Instruments
-0.47%
-0.29%
-1.17%
+0.17%
-0.13%
-1.16%
-3.02%
-0.29%
-1.14%
+1.25%
+1.29%
-0.41%
-0.70%
-0.33%
-0.21%
-0.61%
0.00%
-1.55%
-1.62%
